With many small biotech companies teetering at the edge of a financial precipice, the US government should act swiftly to enact tax benefits allowing a refund of net operating losses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M.K. is on the board of directors of the Biotechnology Industry Association and Symphony Capital, of which he is a managing director, and which funds drug development in collaboration with biotechnology companies.
Rights and permissions
About this article
Cite this article
Kessel, M. A lifeline for the biotech sector. Nat Biotechnol 27, 123–124 (2009). https://doi.org/10.1038/nbt0209-123
Issue Date:
DOI: https://doi.org/10.1038/nbt0209-123
This article is cited by
-
Governments fiddle while biotech burns
Nature Biotechnology (2009)
